We showed that significantly more pathogenic mutations from TP53, BRCA2, and RECQL4 occurred in patients with ESCC than in control cohorts, which indicates that these three CSGs may play vital roles in ESCC. This evidence concerns the gene RECQL4 and esophageal squamous cell carcinoma.